Annovis Bio (NYSE American: ANVS)

ANVS · NYSE American · United States

Share price · ANVS

$0.84-0.96 (-53.28%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.3M (0.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ANVS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-19.0%
  2. 6 Nov 2026+26.3%
  3. 5 Nov 2026-44.7%
  4. 30 Oct 2026+10.8%
  5. 3 Sep 2026-18.8%
  6. 17 Aug 2026-5.9%
  7. 4 May 2026+14.0%

    Nothing announced by ANVS that day or the session before.

  8. 9 Apr 2026-29.6%
  9. 25 Mar 2026-6.3%
  10. 16 Mar 2026+12.3%

Share of unusual movement by asset

For each asset, the share of ANVS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Buntanetap
events and moves
1225%
Other company news (earnings, financing, releases naming no asset)—27%
Sessions with no dated event—47%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
APP/tau/alpha-synuclein/TDP-43 (translation)Small molecule
Alzheimer's DiseaseParkinson's Disease
Early Alzheimer's Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
BuntanetapPhase 3Early Alzheimers Disease
Est. primary completion 2027-12 · NCT06709014 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
BuntanetapPhase 2/3Parkinson's Disease (PD), Deep Brain Stimulation
Est. primary completion 2029-09 · NCT07284784 · CT.gov ↗
What to watch
2030 (1)
February 2030 (1)
BuntanetapPhase 2/3Alzheimer's Dementia (AD)
Est. primary completion 2030-02-21 · NCT07757204 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 July 2024Topline resultBuntanetapPhase 3 Parkinson's disease topline efficacy data released
Annovis Bio (NYSE American: ANVS) · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$16M$2.8M$9.5M-$16M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$12M$19M$15M-$22M operating cash flowreport ↗
2026-Q1$0$17M$14M$18M-$9.0M operating cash flowreport ↗
2025-Q3—$6.3M$15M$7.3M-$3.5M operating cash flowreport ↗
2025-Q2—$5.2M$17M$6.2M-$5.1M operating cash flowreport ↗
2025-Q1$0$5.0M$22M$5.5M-$8.1M operating cash flowreport ↗
2024-Q3—$2.7M$13M$13M-$3.2M operating cash flowreport ↗
2024-Q2—$5.8M$4.0M$5.0M-$3.4M operating cash flowreport ↗
2024-Q1$0$6.5M$3.1M$1.1M-$7.0M operating cash flowreport ↗
2023-Q3—$14M$6.3M$15M-$9.4M operating cash flowreport ↗
2023-Q2—$8.3M$16M$9.5M-$9.6M operating cash flowreport ↗
2023-Q1$0$7.8M$17M$9.7M-$12M operating cash flowreport ↗
2022-Q3—$5.3M$32M$7.6M-$4.0M operating cash flowreport ↗
2022-Q2—$6.8M$36M$8.7M-$6.7M operating cash flowreport ↗
2022-Q1$0$2.8M$43M$5.9M-$3.0M operating cash flowreport ↗
2021-Q3—$1.4M$47M$2.9M-$1.7M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$25M$20M$7.2M-$26M operating cash flowreport ↗

Annovis Bio reported revenue of $0M for fiscal 2025 (prior year $0M), R&D spend of $25.22M, up 26.1% YoY, and cash and equivalents of $19.53M at year-end. The company reported a net loss of $28.85M.

The company estimates its current cash will fund operations into the third quarter of 2026. During 2025, Annovis launched a pivotal Phase 3 trial of buntanetap in early Alzheimer’s disease, reached 65% enrollment by March 2026, received a positive DSMB safety recommendation at six months, reported biomarker data from prior AD and PD programs, and initiated an open-label extension study in Parkinson’s disease. It also transferred its patents to a new crystal form of buntanetap, extending intellectual property protection to 2047, and expanded its management team.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$20M$11M$6.2M-$22M operating cash flowreport ↗
2023-FY$0$39M$5.8M$14M-$40M operating cash flowreport ↗
2022-FY$0$17M$28M$6.3M-$17M operating cash flowreport ↗
2021-FY$0$8.5M$46M$3.6M-$9.1M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 17 purchases ($7.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-06Hoffman Michael B · directorOpen-market purchase5,000,000$1.00$5.0MForm 4
2026-11-06Hoffman Michael B · directorOpen-market purchase (derivative)5,000,000$0.00$0Form 4
2026-05-20Hoffman Michael B · directorOpen-market purchase2,562$1.75$4KForm 4
2026-05-20Hoffman Michael B · directorOpen-market purchase18,849$1.80$34KForm 4
2026-05-20Hoffman Michael B · directorOpen-market purchase54,933$1.90$104KForm 4
2026-04-02Hoffman Michael B · directorOpen-market purchase713,800$2.10$1.5MForm 4
2025-12-08Hoffman Michael B · directorOpen-market purchase30,000$4.34$130KForm 4
2025-12-08Hoffman Michael B · directorOpen-market purchase15,000$4.24$64KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 4.7M shares ($10.3M, 11.1% of shares outstanding).

#InstitutionSharesValue
1MARSHALL WACE, LLP1,187,499$2.6M
2VANGUARD CAPITAL MANAGEMENT LLC872,381$1.9M
3TWO SIGMA INVESTMENTS, LP627,659$1.4M
4RENAISSANCE TECHNOLOGIES LLC347,600$775K
5GEODE CAPITAL MANAGEMENT, LLC247,513$552K
6SUSQUEHANNA INTERNATIONAL GROUP, LLP218,336$487K
7NORTHERN TRUST CORP141,730$316K
8BlackRock, Inc.139,533$311K
9VANGUARD FIDUCIARY TRUST CO132,042$294K
10Merit Financial Group, LLC81,316$181K
11STATE STREET CORP77,735$173K
12GROUP ONE TRADING LLC69,663$155K
13Sherry Group, Inc.57,270$128K
14Wescott Financial Advisory Group, LLC41,607$93K
15First National Trust Co40,000$89K